JP2023529812A5 - - Google Patents
Info
- Publication number
- JP2023529812A5 JP2023529812A5 JP2022572309A JP2022572309A JP2023529812A5 JP 2023529812 A5 JP2023529812 A5 JP 2023529812A5 JP 2022572309 A JP2022572309 A JP 2022572309A JP 2022572309 A JP2022572309 A JP 2022572309A JP 2023529812 A5 JP2023529812 A5 JP 2023529812A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr tki
- pharmaceutically acceptable
- acceptable salt
- generation
- tki
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063030372P | 2020-05-27 | 2020-05-27 | |
| US63/030,372 | 2020-05-27 | ||
| PCT/EP2021/063992 WO2021239786A1 (en) | 2020-05-27 | 2021-05-26 | Egfr tkis for use in the treatment of non-small cell lung cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023529812A JP2023529812A (ja) | 2023-07-12 |
| JP2023529812A5 true JP2023529812A5 (enExample) | 2024-06-03 |
Family
ID=76181131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022572309A Pending JP2023529812A (ja) | 2020-05-27 | 2021-05-26 | 非小細胞肺癌の治療に使用するためのｅｇｆｒ ｔｋｉ |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20210369709A1 (enExample) |
| EP (1) | EP4157267B1 (enExample) |
| JP (1) | JP2023529812A (enExample) |
| KR (1) | KR20230017830A (enExample) |
| CN (2) | CN115776889A (enExample) |
| AU (1) | AU2021279171A1 (enExample) |
| BR (1) | BR112022023519A2 (enExample) |
| CA (1) | CA3183434A1 (enExample) |
| DK (1) | DK4157267T3 (enExample) |
| FI (1) | FI4157267T3 (enExample) |
| IL (1) | IL298216A (enExample) |
| MX (1) | MX2022014903A (enExample) |
| TW (1) | TW202216149A (enExample) |
| WO (1) | WO2021239786A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022526159A (ja) | 2019-03-29 | 2022-05-23 | アストラゼネカ・アクチエボラーグ | 非小細胞肺がんの治療に使用するためのオシメルチニブ |
| US12649792B2 (en) | 2019-05-06 | 2026-06-09 | Brown University | Bispecific antibodies against CHI3L1 and PD1 with enhanced T cell-mediated cytotoxic effects on tumor cells |
| WO2024059962A1 (en) * | 2022-09-19 | 2024-03-28 | Shanghai Allist Pharmaceuticals Co., Ltd. | Pharmaceutical composition and use thereof |
| WO2024118611A2 (en) * | 2022-11-28 | 2024-06-06 | Brown University | Treatment of epidermal growth factor receptor mutant non-small cell lung cancer |
| CN117298116A (zh) * | 2023-08-08 | 2023-12-29 | 江苏晨泰医药科技有限公司 | 盐酸佐利替尼制剂 |
| CN121177212B (zh) * | 2025-11-25 | 2026-03-03 | 中南大学湘雅二医院 | 一种用于治疗egfr突变非小细胞肺癌脑膜转移的药物、应用、药盒及药物的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10063435A1 (de) | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| HRP20110958T1 (hr) | 2004-05-06 | 2012-01-31 | Warner-Lambert Company Llc | 4-fenilaminokinazolin-6-ilamidi |
| DK3686193T3 (da) * | 2011-07-27 | 2022-05-30 | Astrazeneca Ab | 2-(2,4,5-substitueret anilino)pyrimidinforbindelser |
| US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
| JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| LT2964638T (lt) | 2013-03-06 | 2017-12-27 | Astrazeneca Ab | Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai |
| ES3069593T3 (en) | 2013-08-23 | 2026-06-09 | Neupharma Inc | Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer |
| GB201400034D0 (en) | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| US20170166598A1 (en) | 2014-05-13 | 2017-06-15 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| CN105315259B (zh) | 2014-07-29 | 2018-03-09 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物、其制备方法及应用 |
| EP3205650B1 (en) | 2014-10-11 | 2021-08-04 | Shanghai Hansoh Biomedical Co., Ltd. | Egfr inhibitor, and preparation and application thereof |
| EP3929190B1 (en) | 2014-10-13 | 2024-12-25 | Yuhan Corporation | Compounds and compositions for modulating egfr mutant kinase activities |
| CN111170998B (zh) | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| AU2015360360B2 (en) | 2014-12-11 | 2020-06-25 | Beta Pharma (Shanghai) Co., Ltd. | Substituted 2-anilinopyrimidine derivatives as EGFR modulators |
| CN107614503B (zh) | 2015-04-29 | 2020-03-10 | 广东众生药业股份有限公司 | 稠环或三环芳基嘧啶化合物用作激酶抑制剂 |
| EP3661519A1 (en) * | 2017-08-03 | 2020-06-10 | Novartis AG | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor |
-
2021
- 2021-05-25 US US17/329,229 patent/US20210369709A1/en not_active Abandoned
- 2021-05-26 IL IL298216A patent/IL298216A/en unknown
- 2021-05-26 CA CA3183434A patent/CA3183434A1/en active Pending
- 2021-05-26 CN CN202180037402.7A patent/CN115776889A/zh active Pending
- 2021-05-26 AU AU2021279171A patent/AU2021279171A1/en active Pending
- 2021-05-26 FI FIEP21728553.5T patent/FI4157267T3/fi active
- 2021-05-26 WO PCT/EP2021/063992 patent/WO2021239786A1/en not_active Ceased
- 2021-05-26 JP JP2022572309A patent/JP2023529812A/ja active Pending
- 2021-05-26 EP EP21728553.5A patent/EP4157267B1/en active Active
- 2021-05-26 KR KR1020227045541A patent/KR20230017830A/ko active Pending
- 2021-05-26 BR BR112022023519A patent/BR112022023519A2/pt unknown
- 2021-05-26 CN CN202610610034.5A patent/CN122376595A/zh active Pending
- 2021-05-26 MX MX2022014903A patent/MX2022014903A/es unknown
- 2021-05-26 DK DK21728553.5T patent/DK4157267T3/da active
- 2021-05-27 TW TW110119170A patent/TW202216149A/zh unknown
-
2024
- 2024-04-15 US US18/635,697 patent/US20240423978A1/en not_active Abandoned
-
2025
- 2025-04-07 US US19/171,900 patent/US20250325543A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102612513B1 (ko) | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제 | |
| KR102396864B1 (ko) | 6-(2-히드록시-2-메틸프로폭시)-4-(6-(6-((6-메톡시피리딘-3-일)메틸)-3,6-디아자비시클로[3.1.1]헵탄-3-일)피리딘-3-일)피라졸로[1,5-a]피리딘-3-카르보니트릴을 포함하는 제제 | |
| JP2024532734A (ja) | 複素環式化合物及び使用方法 | |
| JP2022184886A5 (enExample) | ||
| CN113474337A (zh) | 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物 | |
| CN109789143A (zh) | 基于嘧啶的抗增殖剂 | |
| AR087336A1 (es) | Compuestos de 2-(2,4,5-anilino sustituido)pirimidina | |
| TW201201811A (en) | Heteroaryl imidazolone derivatives as JAK inhibitors | |
| JP2022500383A (ja) | Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物 | |
| KR20230017830A (ko) | 비소세포폐암의 치료에 사용하기 위한 egfr tki | |
| JP2025510910A5 (enExample) | ||
| JP2025516543A5 (enExample) | ||
| JP2025510910A (ja) | 癌の処置のための、ａｋｔ阻害剤との組み合わせにおける上皮成長因子受容体（ｅｇｆｒ）チロシンキナーゼ阻害剤 | |
| JP2023510426A (ja) | 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤 | |
| KR20250151363A (ko) | 골수증식성 신생물의 치료 방법 | |
| WO2023114225A1 (en) | Pharmaceutical combination comprising abemaciclib and a pi3k and/or a mtor inhibitor for the treatment of mantle cell lymphoma | |
| US12390420B1 (en) | Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof | |
| TW202131922A (zh) | 用於治療癌症的表皮生長因子受體酪胺酸激酶抑制劑 | |
| HK40120753A (en) | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer | |
| WO2025179032A1 (en) | Methods of treating myelofibrosis | |
| CN116490507A (zh) | 用于治疗癌症的杂环包缩合cdc7激酶抑制剂 | |
| JP2025522965A (ja) | 癌の治療のためのｈｇｆ受容体阻害剤と組み合わせた上皮成長因子受容体チロシンキナーゼ阻害剤 | |
| WO2026097025A1 (en) | Polymorphic forms of kras inhibitors and uses thereof | |
| WO2025222187A1 (en) | Compounds and uses thereof | |
| HK40078282A (en) | Btk inhibitors for treating splenomegaly |